David McWilliams, CEO of Opexa Therapeutics Inc., presides over the closing bell.

Monday, September 18, 2006
at NASDAQ's MarketSite
in New York City.

Opexa Therapeutics Inc
[OPXA]

David McWilliams, CEO of Opexa Therapeutics Inc.(OPXA) presides over the closing bell.
Opexa Therapeutics develops and commercializes cell therapies to treat several major disease areas such as MS, rheumatoid arthritis, pancreatic and cardiac conditions. Opexa has exclusive license from Baylor College of Medicine for individualized cell therapies and has initiated a Phase IIb clinical trial to evaluate effectiveness in treating MS. The Company holds the exclusive worldwide license for an autologous T cell vaccine for rheumatoid arthritis from the Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences of the People's Republic of China. Opexa also holds the exclusive worldwide license from the University of Chicago, through its prime contractor relationship with Argonne National Laboratory, for patents relating to the use of adult pluripotent stem cells derived from patients' own circulating blood. For more information, visit the Opexa Therapeutics website at www.opexatherapeutics.com.

Reprints

Click for larger pictures of the NASDAQ MarketSite. Additional Photographs for 9/18/2006 Download Hi-Res Quality Photo of this NASDAQ Market Close - Pictured: David McWilliams, CEO of Opexa Therapeutics Inc., rings the Closing Bell These photos are Copyright 2006, The Nasdaq Stock Market Inc. and available for re-publication by the news media only. Any commercial use is strictly prohibited without the prior written consent of The Nasdaq Stock Market Inc. © Copyright 2006, The NASDAQ Stock Market, Inc. Reprinted with the permission of The Nasdaq Stock Market, Inc.